Paper Details

  1. Home
  2. Paper Details

Boceprevir for previously treated chronic HCV genotype 1 infection.

Author: , AlbrechtJanice K, BaconBruce R, BoparaiNavdeep, BrassClifford A, BurroughsMargaret, EstebanRafael, GoodmanZachary D, GordonStuart C, LawitzEric, MarcellinPatrick, PoordadFred, SingsHeather L, VierlingJohn M, ZeuzemStefan

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the potential role of boceprevir, a protease inhibitor, as an additional treatment option for patients with chronic hepatitis C virus (HCV) genotype 1 infection who do not respond to peginterferon-ribavirin therapy.
Paper Details　
Original Abstract of the Article :
In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been sugge...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/21449784

データ提供：米国国立医学図書館（NLM）

Boceprevir for Chronic HCV Genotype 1: A New Oasis in the Desert of Hepatitis C

Imagine a vast desert where a stubborn illness, like a persistent sandstorm, threatens the well-being of individuals. This research explores the potential of boceprevir, a protease inhibitor, in treating chronic hepatitis C virus (HCV) genotype 1 infection.

The study focuses on patients who had not responded to previous treatments with peginterferon-ribavirin, a common approach for managing HCV. Boceprevir, like a new tool in a camel caravan's arsenal, offers a promising alternative for these challenging cases.

A New Hope in the Desert of HCV

The findings suggest that boceprevir could be a valuable addition to the treatment regimen for chronic HCV genotype 1 infection. It's like discovering a new oasis in a parched desert, offering a chance for relief and potential recovery.

Navigating the Desert of HCV Treatment

If you are struggling with chronic HCV, it's essential to consult with a healthcare provider and explore the latest treatment options. Remember, a well-informed camel caravan can navigate the desert of illness with greater confidence and success.

Dr.Camel's Conclusion

Boceprevir, like a refreshing oasis in the desert of HCV, offers hope for patients who have not responded to previous treatments. This research provides valuable insights into the potential of new medications for managing this challenging viral infection.

Date :
  1. Date Completed 2011-04-05
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

21449784

DOI: Digital Object Identifier

NIHMS312445

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.